





30

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/837,539 04/18/2001		John M. Barker	1032-P02148US1	7584	
	590 12/03/2002				
	FMAN HERRELL &	EXAM	EXAMINER		
SUITE 720 1601 MARKE		MARMOR II, CHARLES ALAN			
PHILADELPH	IIA, PA 19103-2307		ART UNIT	PAPER NUMBER	
			3736		

DATE MAILED: 12/03/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

					;			
		Application No.		Applicant(s)				
	Office Action 0	09/837,539	` =	BARKER ET AL.	C:II			
	Office Action Summary	Examiner	·	Art Unit				
		Charles A. Marm		3736				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
THE - Exte after - If the - If NC - Failu - Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nations of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, hower within the statutory min will apply and will expire a cause the application to	ever, may a reply be tim simum of thirty (30) days SIX (6) MONTHS from	ely filed s will be considered timely the mailing date of this co	: mmunication.			
1)	Responsive to communication(s) filed on 22 C	October 2002						
2a)□		is action is non-fi	nal.		•			
3)	·							
Dispositi	closed in accordance with the practice under <i>l</i> ion of Claims	Ex parte Quayle,	1935 C.D. 11, 4	53 O.G. 213.				
·	Claim(s) 1.2.5 and 8-20 is/are pending in the a	application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
6)⊠	S)⊠ Claim(s) <u>1,2,5 and 8-20</u> is/are rejected.							
7)								
8)□	Claim(s) are subject to restriction and/or	election require	ment.					
Applicati	on Papers							
9)[]	The specification is objected to by the Examiner							
10)🖾	The drawing(s) filed on <u>10 April 2001</u> is/are: a)[$ ceil$ accepted or b) $ lap{ extstyle oxed{oxed}}$	objected to by th	e Examiner.				
	Applicant may not request that any objection to the							
11)[]	The proposed drawing correction filed on	• • •	. —	ved by the Examine	r.			
If approved, corrected drawings are required in reply to this Office action.								
	The oath or declaration is objected to by the Exa	aminer.						
	inder 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a)[☐ All b)☐ Some * c)☐ None of:							
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
* S	 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14)⊠ A	cknowledgment is made of a claim for domestic	priority under 35	5 U.S.C. § 119(e)	(to a provisional	application).			
	The translation of the foreign language provinces to the translation of the foreign language provinces.	• •						
Attachment		, ,	. 00					
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲	Notice of Informal Page	(PTO-413) Paper No(s atent Application (PTO				

DETAILED ACTION

1. This Office Action is responsive to the Response to Office Action filed October 22, 2002. The examiner acknowledges the amendments to claims 1, 2, 5, and 8; the cancellation of claims 3, 4, 6 and 7; and the addition of new claims 9-20. Claims 1, 2, 5 and 8-20 are pending.

Drawings

The following objections to the drawings were made in the Office Action mailed June 14, 2002. The Response to Office Action filed October 22, 2002 was not responsive to these drawing objections:

- 2. The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they do not include the following reference sign(s) mentioned in the description: "240" as described on page 18, lines 6-8 and 10. A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.
- 3. The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they include the following reference sign(s) not mentioned in the description: "454" as illustrated in Figures 15 and 16. A proposed drawing correction, corrected drawings, or amendment to the specification to add the reference sign(s) in the description, are required in reply to the Office

Art Unit: 3736

action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.

4. The drawings are objected to because in Figure 18 the uppermost occurrence of reference sign "492" apparently should be deleted. A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.

Specification

5. The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Claim Objections

The following objections to the claims were made in the Office Action mailed June 14, 2002. The Response to Office Action filed October 22, 2002 was not responsive to these claim objections:

6. Claims 1 and 8 are objected to because of the following informalities: in line 6,
--;-- apparently should be inserted after "element". Appropriate correction is required.

Application/Control Number: 09/837,539

Art Unit: 3736

Claim Rejections - 35 USC § 112

Page 4

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the

subject matter which the applicant regards as his invention.

8. Claims 17 and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite

for failing to particularly point out and distinctly claim the subject matter which applicant

regards as the invention.

Claims 17 and 19 recite the limitation "the shielded position" in lines 1-2. There is

insufficient antecedent basis for this limitation in the claim. There is no shielded position recited

in the claims prior to this recitation.

Claim Rejections - 35 USC § 102

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the

basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on

sale in this country, more than one year prior to the date of application for patent in the United States.

10. Claims 1, 2, 5 and 8-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Yoon

('053). Yoon teaches a safety needle instrument having a triggered safety member. The Yoon

instrument is a medical device including a hollow housing 328; a needle 324 having a sharpened

tip 330 projecting forwardly from the housing; a spring biasing element 354 biasing the needle

rearwardly; a needle retainer 386,394 releasably retaining the needle against the rearward bias of

the biasing element; and a flexible shield 371 fixedly attached to the housing, projecting

forwardly from the housing. The shield is configured for insertion into a patient. The shield sheathes the needle such that in a projecting position the sharpened tip of the needle projects beyond the forward edge of the shield, and in a retracted position the sharpened tip is enclosed within the shield. The shield is substantially puncture resistant so that the axial force required to buckle the shield is less than the force necessary to puncture the shield with the needle in order to prevent inadvertent contact with the contaminated needle. A lock 374 for locking the needle in the retracted position; a connector 104 in fluid communication with the needle for attaching to a fluid device; and a stop 336 for limiting the displacement of the needle may also be provided.

In operation, the needle is inserted into the patient; the actuator 394 of the needle retainer is actuated such that the biasing element displaces the needle so the needle is locked in a shielded position; and fluid is infused or blood is collected through the shielded needle by the fluid device connected to connector 104.

Double Patenting

11. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Application/Control Number: 09/837,539

Art Unit: 3736

12. Claims 1, 8, 11 and 15 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 16, 18, 22, 24 and 28 of U.S. Patent No. 6,398,743. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant application and the patent teach a medical device including a needle having a sharpened tip; a biasing element for biasing the needle rewardly; a needle retainer releasably retaining the needle against the bias of the biasing element; a shield that is substantially incompressible axially; and a connector for attaching to a fluid device, where the needle has a projecting position and a retracted position. As such, the claims of the patent and the claims of the instant application recite the same structural elements of the medical device and differ only in the intended use of the respective medical devices. Since the claims of the patent "anticipate" the claims of the instant application, the claims are not patentably distinct.

Page 6

13. Claims 5 and 20 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 2, 7-9, 11 and 15 of U.S. Patent No. 6,398,743. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the patent recite all of the method steps of the method claimed in claims 5 and 20 of the instant application with additional steps for inserting a guide wire into the patient. Since the narrower claims of the patent "anticipate" the broader claims of the instant application, the claims are not patentably distinct.

Application/Control Number: 09/837,539 Page 7

Art Unit: 3736

Response to Arguments

14. Applicant's arguments with respect to claims 1-8 have been considered but are moot in view of the new ground(s) of rejection. Applicant argues that Song et al. is not directed to a safety device and that the injection tube of Song et al. does not provide any type of safety feature to protect the needle. Applicant further contends that Song et al. does not teach or suggest a shield that is substantially puncture resistant or retracting a needle into such a shield; a biasing element; or a needle retainer. These arguments are moot in view of the cancellation of claims 3, 4, 6 and 7 and the new grounds of rejection made hereinabove.

Conclusion

- 15. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Haughton et al. teach a catheter trocar retraction system. Botich et al. teach a catheter insertion device with a retractable needle.
- 16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles A. Marmor, II whose telephone number is (703) 305-3521. The examiner can normally be reached on M-TH (7:00-5:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Max Hindenburg can be reached on (703) 308-3130. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3590 for regular communications and (703) 308-0758 for After Final communications.

Application/Control Number: 09/837,539

Art Unit: 3736

Page 8

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-0858.

Charles A. Marmor, II

Examiner Art Unit 3736

CAM

December 1, 2002